Table 1 Mitophagy inhibitors and inducers in anticancer therapeutics
From: Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics
No | Drug | Mitophagy inhibitor or inducer | Mechanisms in anticancer therapeutics |
|---|---|---|---|
1 | Melatonin | Inhibitor | Downregulates c-Jun N-terminal kinase (JNK) and subsequently Parkin, and aggravates cell apoptosis [85] |
2 | Mdivi-1 | Inhibitor | Increases the susceptibility of hepatic cancer cells to cisplatin by increasing mitochondrial membrane permeability [86] |
3 | Liensinine | Inhibitor | Suppresses the excessive accumulation of autophagosomes, autophagosome-lysosome fusion and the maturation of several important lysosomal hydrolases [87] |
4 | Ketoconazole | Inducer | Induces PINK1-Parkin mitophagy pathway by downregulating the expression of COX-2 and promotes the apoptosis of hepatic carcinoma cells [88] |
5 | Sorafenib | Inducer | Stabilizes PINK1 on the outer membrane of mitochondria and recruits Parkin to dysfunctional mitochondria to initiate mitophagy in liver cancer cells [89] |
6 | Mito-CP and Mito-Metformin | Inducer | Release ULK1 from mTOR-mediated inhibition, decrease mitochondrial membrane potential, and abrogate colorectal cancer cell proliferation [90] |